Our research focuses on the five core coverage areas below. We apply our rigorous research methodology to our reports, charts, forecasts, and more to keep our clients at the forefront of key developments and trends before they hit the mainstream.
Insider Intelligence delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
Our goal at Insider Intelligence is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
The trend: Pressure is growing on drug makers to curb the cost of insulin to diabetes patients.
On March 1, President Biden praised Eli Lilly for its $35 cap on patients’ out-of-pocket cost for its insulin products.
On March 9, Sen. Bernie Sanders (I-VT), head of the Senate Health, Education, Labor, and Pensions (HELP) Committee, proposed legislation to limit the list price of insulin to $20 per vial.
Two weeks later, on March 14, Novo Nordisk, one of the largest global insulin makers, announced it would cut US list prices by up to 75%.
French drugmaker Sanofi, another major insulin seller, has not announced price changes currently.
How we got here:Insulin prices in the US have skyrocketed more than 600% over the last 20 years, per a September 2022 NPR report.
In the case of Novo’s NovoLog, a five-pack of injection pens are listed at $559, and a vial is $298.
After the cost cuts take effect in January 2024, prices would drop to $140 for the pens and $72 for the vial, per the Wall Street Journal.
Patients aren’t the only ones concerned about the cost of diabetes treatment. US employers pay approximately $245 billion each year to cover treatment and drugs for diabetic employees, per a study by Nomi Health.
Of that, $175 billion annually goes to direct medical and pharmacy costs.
$70 billion is the indirect cost to employers from employee absenteeism, reduced productivity, and diabetes-related disability, the study showed.
The pressure heats up: Healthcare is already a hot topic in 2023, as the US presidential campaigns get under way. Consumers are paying attention.
53% of US adults polled by The Economist and YouGov in early March said either they or someone they know uses insulin.
73% either strongly or somewhat support laws that set limits on how much companies can charge for insulin (53% strongly and 20% somewhat).
Our take: Drug prices are a major concern for Americans, and they’re ready for the government to help.
37% of respondents in the Economist/YouGov poll said they hadn’t filled a prescription because they couldn’t afford it.
Consumers will spend $224 per person (including children) this year, and we project that cost will rise to$279 per person in 2026.
This article originally appeared inInsider Intelligence'sDigital Health Briefing—a daily recap of top stories reshaping thehealthcareindustry. Subscribe to have more hard-hitting takeaways delivered to your inbox daily.